PhRMA Continues Critique of ICER Drug Pricing Studies

The Pharmaceutical Research and manufacturers of America (PhRMA) have repeatedly spoken out against the cost-effectiveness studies published by the Institute for Clinical and Economic Review (ICER) and has recently publicized its own four pointed list of recommendations to ICER. Read more here. (Source: Joe Cantlupe, BioPharma DIVE, 9/29/16)

You might also be interested in:

What Does $11M in Donations to Congress Buy Pharma? 08/12/2020
New Program in Pharmaceutical Value Assessment and… 01/22/2021
What Are The Recent Top 4 Innovative Consolidations and… 08/26/2020
How HEOR Professionals Can Be Force Multipliers in the Fight… 10/06/2020
Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020
Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020
Government, Big Pharma, and The People: A Century of Dis-Ease 12/03/2020